Search Results
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
approved treatments which slow or halt disease progression. SKY-0515 is an orally-administered, investigational small molecule RNA modulator developed through the company's novel RNA-modulating platform, SKYSTAR®. SKY-0515 therapeutically reduces both HTT protein and PMS1 protein. PMS1 is
More news about: Skyhawk Therapeutics
Jan 27, 2026, 03:28 ET Libevitug Approved in China as First-in-Class Hepatitis D Treatment
The drug also showed favorable tolerability and a satisfactory safety profile. At Week 48, the combined response rate reached 44.1%, along with an HDV RNA virological response rate of 60% and an ALT normalization rate of 70%, and a significant, sustained improvement in liver stiffness. Libevitug is poised
More news about: Huahui Health Ltd.
Jan 27, 2026, 03:00 ET Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
mechanism: refractory epilepsy, rare movement disorders, and neuromuscular diseases. Servier R&D is focused on small molecules that target messenger RNA, particularly antisense oligonucleotides (ASOs), as well as pharmacological molecules and monoclonal antibodies. To date, the neurology pipeline comprises
More news about: Servier
Jan 27, 2026, 03:00 ET Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
mechanism: refractory epilepsy, rare movement disorders, and neuromuscular diseases. Servier R&D is focused on small molecules that target messenger RNA, particularly antisense oligonucleotides (ASOs), as well as pharmacological molecules and monoclonal antibodies. To date, the neurology pipeline comprises
More news about: Servier
Jan 21, 2026, 09:08 ET Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) for Reproducible Retinal Research
distribution infrastructure. This new recombinant mAb replaces the formerly available guinea pig polyclonal RBPMS Antibody (Cat. No. 1832-RBPMS).RBPMS (RNA Binding Protein with Multiple Splicing) has emerged as the gold-standard marker for identifying retinal ganglion cells, supporting accurate cell
More news about: Antibodies Inc.
Jan 21, 2026, 08:30 ET NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About NeuroSense NeuroSense Therapeutics, Ltd. is a clinical-stage
More news about: NeuroSense
Jan 20, 2026, 13:53 ET Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies
normalizing ~75% of upregulated genes (including Lrrk2) and counteracting the disease-associated microglial phenotype identified by human single-cell RNA sequencingLowered plasma neurofilament light (NfL) and IL-18, biomarkers that correlated strongly with motor improvementThese effects
More news about: Olatec Therapeutics, Inc.
Jan 20, 2026, 10:30 ET Nucleic Acid Isolation and Purification Market worth $10.99 billion by 2030 | MarketsandMarkets™
accounted for the dominant share of the global nucleic acid isolation and purification market.the market is segmented into DNA isolation kits, RNA isolation kits, total nucleic acid isolation kits, and other kits. In 2024, the DNA isolation kits segment accounted for the largest share of the nucleic
More news about: MarketsandMarkets
Jan 20, 2026, 04:17 ET Tsingke Biotech Launches New Website to Streamline Global Biotech R&D and Translational Services
key areas: Product Capabilities, Application Scenarios, and Technical Support. Tsingke integrates core technologies — including nucleic acids, RNA, proteins, antibodies, and viral vectors — into seamless workflows that accelerate project timelines and reduce development risks.Services are
More news about: Beijing Tsingke Biotech Co., Ltd.
Jan 15, 2026, 16:06 ET Disrupting Biotech: Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable
Unlike the metallic robots of science fiction, these biological machines are designed to produce fluorescent signals when they encounter specific DNA or RNA molecules, enabling rapid, accurate point-of-care diagnostics."We are creating nanorobots that self-assemble into structures or dynamic devices,"
More news about: Disruption Interruption
Jan 13, 2026, 20:22 ET 管線成果超預期，獲數千萬港幣里程碑付款！晶泰科技賦能AI+RNA新藥RTX-117獲中美臨床批件
深度合作的一系列研發管線中首個里程碑成果，其臨床前數據及臨床獲批速度均超出雙方預期。即將開展的臨床研究將評估該突破性療法的安全性和有效性，為全球數百萬受 CMT 及相關疾病困擾的患者帶來潛在的治療希望。關於ReviR Therapeutics (溪礫科技) ReviR Therapeutics 是一家處於臨床階段的全球生物技術公司，致力於結合 AI 技術與 RNA 生物學，開發高特異性、有效且安全的疾病修飾療法。憑借自研平台 VoyageR 深厚的技術積澱，ReviR 已在神經系統疾病和自身免疫領域佈局多條創新藥管線。其主要候選小分子藥物 RTX-117 當前正推進針對腓骨肌萎縮症（CMT）的臨床試驗，並持續拓展新適應症。關於晶泰科技晶泰科技（「XtalPi
More news about: 晶泰科技
Jan 13, 2026, 09:15 ET Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
Illumina Single Cell 3' RNA prep platform, which enables millions of individual cells to be captured in a single experiment. The Atlas will generate data at a rate of 20 petabytes of single-cell transcriptomic data within a year. To handle data of this magnitude, single-cell RNA-sequencing data is processed
More news about: Illumina, Inc.
Jan 13, 2026, 09:09 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow on
More news about: EspeRare Foundation
Jan 13, 2026, 07:30 ET Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
TherapeuticsRactigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™,
More news about: Ractigen Therapeutics
Jan 13, 2026, 03:00 ET n-Lorem und EspeRare kündigen europäische Zusammenarbeit zur Erweiterung des Zugangs zu individualisierten ASO-Therapien für seltene genetische Erkrankungen an
Präsidenten und CEO von Ionis Pharmaceuticals, gegründet. Er gründete das Unternehmen 1989 und entwickelte es zu einem weltweit führenden Anbieter von RNA-basierten Therapien. Folgen Sie uns auf
More news about: EspeRare Foundation
Jan 12, 2026, 13:43 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow on
More news about: EspeRare Foundation
Jan 12, 2026, 10:00 ET Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection
because the early biological signals of cancer in the blood can be subtle and hard to identify. Freenome's multiomics platform profiles DNA methylation, RNA, protein and other analytes, and for each individual, generates billions of data points across different modalities. The use of AI/ML and deep learning
More news about: Freenome Holdings, Inc.
Jan 12, 2026, 09:00 ET Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jan 10, 2026, 13:31 ET Ribo Life Science (06938.HK) erfolgreich am Main Board der Hongkonger Börse notiert
/PRNewswire/ -- Ribo Life Science Co., Ltd. („Ribo" oder das „Unternehmen", Aktiencode: 06938.HK), ein führendes Unternehmen im Bereich der Small Interfering RNA (siRNA)-Therapeutika, wurde heute erfolgreich am Main Board der Hongkonger Börse notiert, was einen bedeutenden Meilenstein in der Kapitalisierung chinesischer
More news about: Ribo Life Science
Jan 09, 2026, 10:00 ET Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
and NRG1 fusion interactions with HER3, resulting in the suppression of these pathways. Comprehensive molecular testing, notably tissue-based RNA next generation sequencing, is essential to identify rare and actionable gene fusions like NRG1.About BIZENGRI (zenocutuzumab-zbco)INDICATIONSBIZENGRI
More news about: Partner Therapeutics, Inc.
Jan 09, 2026, 08:00 ET Averna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
insert any gene or genetic instruction of interest safely and efficiently into "safe harbor" sites in the genome. Our platform configures a modular, all-RNA system combined with multiple LNP delivery solutions. This proprietary approach has the potential to expand the reach of genomic medicines, increasing
More news about: Averna Therapeutics
Jan 09, 2026, 07:00 ET Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
Jan 09, 2026, 00:22 ET Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization
More news about: Ribo Life Science
Jan 09, 2026, 00:02 ET Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization
More news about: Ribo Life Science
Jan 08, 2026, 08:45 ET World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About NeuroSenseNeuroSense Therapeutics, Ltd. is a clinical-stage
More news about: NeuroSense